The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975–2004)
TLDR
The first reliable population-based estimates of incidence, patient demographics, treatment course and survival for malignancy in GCT of bone in the United States from 1975-2004 are offered and suggest that age and stage at diagnosis are strongly associated with long-term survival.Abstract:
Malignant giant cell tumor (GCT) of bone is a rare tumor with debilitating consequences. Patients with GCT of bone typically present with mechanical difficulty and pain as a result of bone destruction and are at an increased risk for fracture. Because of its unusual occurrence, little is known about the epidemiology of malignant GCT of bone. This report offers the first reliable population-based estimates of incidence, patient demographics, treatment course and survival for malignancy in GCT of bone in the United States. Using data from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program, we estimated the overall incidence and determinants of survival among patients diagnosed with malignant GCT of bone from 1975–2004. Cox proportional hazards regression was used to evaluate demographic and clinical determinants of survival among malignant GCT cases. Based on analyses of 117 malignant GCT cases, the estimated annual incidence in the United States was 1.6 per 10,000,000 persons per year. Incidence was highest among adults aged 20 to 44 years (2.4 per 10,000,000 per year) and most patients were diagnosed with localized (31.6%) or regional (29.9%) disease compared to distant disease (16.2%). Approximately 85% of patients survived at least 5 years, with survival poorest among older patients and those with evidence of distant metastases at time of diagnosis. The current study represents the largest systematic investigation examining the occurrence and distribution of malignancy in GCT of bone in the general U.S. population. We confirm its rare occurrence and suggest that age and stage at diagnosis are strongly associated with long-term survival.read more
Citations
More filters
Journal ArticleDOI
H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.
Fernanda Amary,Fitim Berisha,Hongtao Ye,Manu Gupta,Alice Gutteridge,Daniel Baumhoer,Rebecca Gibbons,Roberto Tirabosco,Paul O'Donnell,Adrienne M. Flanagan +9 more
TL;DR: The sensitivity and specificity of the anti-histone H3.3 G34W rabbit monoclonal antibody in a wide variety of tumors including histologic mimics of GCTB is investigated to assess its value as a diagnostic marker and it is proposed that subarticular primary malignant bone sarcoma with H2.3 mutations represent true malignant GCTBs, even in the absence of a benign GCTb component.
Journal ArticleDOI
Denosumab and giant cell tumour of bone—a review and future management considerations
TL;DR: Several large phase iii studies have shown that denosumab is more effective than bisphosphonates in reducing skeletal morbidity arising from a wide range of tumours and that it can delay bone metastasis.
Journal ArticleDOI
RANKL, denosumab, and giant cell tumor of bone
TL;DR: Denosumab offers a new treatment option for a subset of patients with previously untreatable GCT, and appears to be well tolerated.
Journal ArticleDOI
Giant cell tumour of bone: new treatments in development
TL;DR: Studies with denosumab, a monoclonal antibody that specifically binds to RANKL, resulted in dramatic treatment responses, which led to its approval by the United States Food and Drugs Administration (US FDA).
Journal ArticleDOI
Incidence Patterns of Primary Bone Cancer in Taiwan (2003–2010): A Population-Based Study
Giun Yi Hung,Jiun Lin Horng,Hsiu Ju Yen,Hsiu Ju Yen,Chueh Chuan Yen,Chueh Chuan Yen,Wei Ming Chen,Wei Ming Chen,Paul Chih-Hsueh Chen,Paul Chih-Hsueh Chen,Hung Ta Hondar Wu,Hung Ta Hondar Wu,Hong Jen Chiou,Hong Jen Chiou,Hong Jen Chiou +14 more
TL;DR: Despite overall low rates, the upward trend in BC incidence among females may invoke a concern, and the results suggest areas for further study into the underlying causes for these cancer trends.
References
More filters
Journal ArticleDOI
Giant-cell tumor of bone.
TL;DR: Of the fifty-one local recurrences that were seen after treatment at the Istituto Rizzoli, 90 per cent appeared in the first three years after surgery, and these results did not correlate with the radiographic grade of the lesion.
Book
Bone tumors, diagnosis, treatment, and prognosis
TL;DR: Describes bone tumors and many non-neoplastic bone conditions important in daily practice of orthopedic pathology and musculoskeletal oncology.
Journal ArticleDOI
A system of staging musculoskeletal neoplasms.
TL;DR: A system for staging benign and malignant musculoskeletal lesions that articulates well with current radiologic techniques of staging and serves as a useful guide in the selection of an appropriate definitive surgical procedure.
Journal ArticleDOI
Giant-cell tumor: a study of 195 cases.
TL;DR: The evidence indicates that surgical removal is the best treatment and that radiation should be employed only for tumors that are unresectable because of their location.
Journal ArticleDOI
Giant cell tumor of long bone: a Canadian Sarcoma Group study.
Robert E. Turcotte,Jay S. Wunder,Marc H. Isler,Robert S. Bell,Norman S. Schachar,Bassam A. Masri,Guy Moreau,Aileen M. Davis +7 more
TL;DR: Results from the Musculoskeletal Tumor Society rating from 1987 were significantly lower in patients who sustained a displaced fracture and results from the bodily pain section of the Short Form-36 also were found to be lower when a pathologic fracture was present.
Related Papers (5)
Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.
Sam Behjati,Sam Behjati,Patrick S. Tarpey,Nadege Presneau,Susanne Scheipl,Susanne Scheipl,Nischalan Pillay,Nischalan Pillay,Peter Van Loo,Peter Van Loo,David C. Wedge,Susanna L. Cooke,Gunes Gundem,Helen Davies,Serena Nik-Zainal,Sancha Martin,Stuart McLaren,Victoria Goodie,Ben Robinson,Adam Butler,Jon W. Teague,Dina Halai,Bhavisha Khatri,Ola Myklebost,Daniel Baumhoer,Gernot Jundt,Rifat Hamoudi,Roberto Tirabosco,M Fernanda Amary,P. Andrew Futreal,Michael R. Stratton,Peter J. Campbell,Peter J. Campbell,Adrienne M. Flanagan,Adrienne M. Flanagan +34 more